The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors

Published:2017-03-06 Issue:6 Volume:16 Page:1021-1030
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Zhang Hui,Patel Atish,Wang Yi-Jun,Zhang Yun-Kai,Kathawala Rishil J.,Qiu Long-Hui,Patel Bhargav A.,Huang Li-Hua,Shukla Suneet,Yang Dong-Hua,Ambudkar Suresh V.,Fu Li-Wu,Chen Zhe-Sheng

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fertility protection: a novel approach using pretreatment with mesenchymal stem cell exosomes to prevent chemotherapy–induced ovarian damage in a mouse model;American Journal of Obstetrics and Gynecology;2024-07

2. Ibrutinib disrupts blood-tumor barrier integrity and prolongs survival in rodent glioma model;Acta Neuropathologica Communications;2024-04-08

3. The role of ABCC10/MRP7 in anti-cancer drug resistance and beyond;Drug Resistance Updates;2024-03

4. Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2;Drug Resistance Updates;2023-11

5. Bruton’s Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux;Pharmaceutics;2022-09-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP